Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

266

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Interventions

DRUG: OLAPARIB
DRUG: Single agent chemotherapy

Sponsor

AstraZeneca

Collaborators

[object Object]
[object Object]